A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Trial Profile

A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs KPT 9274 (Primary) ; Niacin
  • Indications Colon cancer; Lung cancer; Non-Hodgkin's lymphoma; Sarcoma; Solid tumours
  • Focus First in man; Therapeutic Use
  • Acronyms PANAMA
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to a Karyopharm Therapeutics media release, top-line data from this clinical study are expected later this year.
    • 04 May 2017 According to Karyopharm Therapeutics media release, top-line data from this clinical study are expected in mid-2017.
    • 22 Jun 2016 According to Karyopharm Therapeutics media release, the company looks forward to report top line data of this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top